PUBLIC COMPANY
saveVIATRIS
USupdated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- As part of sales reorganization, Novo will cut 215 employees at US HQFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 9h ago
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.biospace · 28d ago
- Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy businessWith an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.biospace · 1mo ago
- Viatris to make $1.65B Pacira acquisition, adding to momentum in painViatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences. The Thursday morning deal, valued at $1.65 bill…endpoints · 1mo ago
- Viatris boosts pain drug portfolio with $1.7B buyout of PaciraThe deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to su…biopharma_dive · 1mo ago
- STAT+: Roche goes beyond licensing in deal with Chinese biotechRoche is partnering with Chinese startup Defand Therapeutics to discover new medicines.stat · 1mo ago
- Merck stages expanded access to monthly HIV PrEP pill ahead of approvalFollowing in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.fiercebiotech · 3mo ago
- Biopharma layoffs must double in H2 for 2026 to match 2025 cutsWith fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on t…biospace · 4mo ago
- Webinar: From Clinical to Commercial: Talent Strategies for Biopharma GrowthThis webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…biospace · 4mo ago
- FDA issues untitled letters to Sanofi and Viatris for false advertisingThe FDA’s Office of Prescription Drug Promotion recently reprimanded Sanofi and Viatris for making misleading claims about their products in emails and a television advertisement.raps · 4mo ago
comments(0)
5-min edit window · permanent after that